Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04556773 · ClinicalTrials.gov registry record · Phase 1

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

A Phase 1 study of Metastatic Breast Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 1
Development phase
138
Enrollment target
20
Study locations

NCT04556773: Active Phase 1 study of Metastatic Breast Cancer, sponsored by AstraZeneca.

NCT04556773 is a Phase 1 study of Metastatic Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 138 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04556773, a Phase 1 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
138 participants
Enrollment target
20
Study locations

Study Summary

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

Primary Outcome

Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0

Conditions Studied

Metastatic Breast Cancer

Interventions

  • DRUG Paclitaxel
  • DRUG Anastrozole
  • DRUG Trastuzumab deruxtecan
  • DRUG Capivasertib
  • DRUG Durvalumab

Study Locations (20)

Other

  • Research Site - East Melbourne
  • Research Site - Westmead
  • Research Site - Edegem
  • Research Site - Leuven
  • Research Site - Ottignies
  • Research Site - Goiânia
  • Research Site - Porto Alegre
  • Research Site - Porto Alegre
  • Research Site - São Paulo
  • Research Site - São Paulo

New York

  • Research Site - Commack
  • Research Site - Harrison
  • Research Site - New York
  • Research Site - New York
  • Research Site - Uniondale

Tennessee

  • Research Site - Chattanooga
  • Research Site - Germantown

North Carolina

  • Research Site - Chapel Hill

Texas

  • Research Site - Fort Worth

British Columbia

  • Research Site - Kelowna

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2020-12-17
Est. Completion 2026-06-16
Phase Phase 1
AstraZeneca

1,285 total trials

What the registry record for NCT04556773 still lists

NCT04556773 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (32% lower).

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.

NCT04556773 names 20 study sites across 6 states, led by Other, New York, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04556773 about?

NCT04556773 is a clinical study titled "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer". DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

What is the current status of trial NCT04556773?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2020-12-17. Estimated completion is 2026-06-16.

What conditions does trial NCT04556773 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT04556773?

The interventions under investigation include: Paclitaxel (DRUG), Anastrozole (DRUG), Trastuzumab deruxtecan (DRUG), Capivasertib (DRUG), Durvalumab (DRUG).

Who is sponsoring clinical trial NCT04556773?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04556773 being conducted?

This trial has 20 study locations across New York, North Carolina, Tennessee, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04556773's enrollment target sits among peer trials

138 45th of 139 higher than 95 of 139 other Metastatic Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04556773, the US trial registry maintained by the National Library of Medicine. NCT04556773 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.